LY 163443

structure in first source; leukotriene receptor antagonist

Also Known As:

1-(2-hydroxy-3-propyl-4-((4-(1H-tetrazol-5-ylmethyl)phenoxy)methyl)phenyl)ethanone; Ethanone, 1-(2-hydroxy-3-propyl-4-((4-(1H-tetrazol-5-ylmethyl)phenoxy)methyl)phenyl)-; LY-163443

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Ketones: 2618
  - Acetophenones: 16
    - LY 163443: 2

Related Diseases

1.	Shock 05/01/1988 - "SAO shock rats pretreated with LY-163443 also exhibited significantly higher survival rates (p less than 0.01 from vehicle and post-treatment groups), and prolonged survival times (p less than 0.01 from vehicle and post-treatment groups).(ABSTRACT TRUNCATED AT 250 WORDS)" 05/01/1988 - "SAO shock rats pre-treated with LY-163443 before the occlusion of the splanchnic arteries maintained post-release MABP at significantly higher values compared to rats receiving either the vehicle or LY-163443 as a post-treatment 15 min after occlusion (final MABP 96 +/- 8 vs 51 +/- 1, p less than 0.01 and 53 +/- 3, p less than 0.01, respectively). " 05/01/1988 - "We studied the effects of LY-163443, a novel selective receptor antagonist of LTD4 and LTE4, in splanchic artery occlusion (SAO) shock. " 05/01/1988 - "Use of a novel peptide leukotriene receptor antagonist, Ly-163443, in splanchnic artery occlusion shock."
2.	Hypoxia (Hypoxemia) 09/01/1989 - "Similarly, the LT receptor antagonists FPL 57231 (3 microM) or LY 163443 (1 microM), at concentrations that inhibited LT-induced venular contractions, did not significantly affect the responses to hypoxia or anoxia. "

Related Drugs and Biologics

1.	Leukotriene Antagonists (Leukotriene Receptor Antagonists)
2.	Leukotriene E4
3.	Leukotriene D4
4.	Peptides (Polypeptides)
5.	FPL 57231